JP2012522763A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522763A5
JP2012522763A5 JP2012503350A JP2012503350A JP2012522763A5 JP 2012522763 A5 JP2012522763 A5 JP 2012522763A5 JP 2012503350 A JP2012503350 A JP 2012503350A JP 2012503350 A JP2012503350 A JP 2012503350A JP 2012522763 A5 JP2012522763 A5 JP 2012522763A5
Authority
JP
Japan
Prior art keywords
diyl
alkyl
group
alkoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012503350A
Other languages
English (en)
Other versions
JP2012522763A (ja
JP5864409B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/PT2010/000014 external-priority patent/WO2010114404A1/en
Publication of JP2012522763A publication Critical patent/JP2012522763A/ja
Publication of JP2012522763A5 publication Critical patent/JP2012522763A5/ja
Application granted granted Critical
Publication of JP5864409B2 publication Critical patent/JP5864409B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. 式Iのニトロカテコール誘導体、その塩、エステル、水和物、溶媒和物及びその他の誘導体から選択される少なくとも1種の活性医薬成分と、少なくとも1種のホスフェート誘導体と、少なくとも1種のポリビニルピロリドン誘導体化合物とを含む組成物であって、 前記少なくとも1種の活性医薬成分が顆粒の形態で存在することを特徴とする組成物。

    下式I、
    Figure 2012522763
    (I)
    (式Iにおいて、
    1及びR2は独立して水素又は生理的条件下で加水分解性の基から選択され、任意で置換された低級アルカノイル又はアロイルであり、
    Xはメチレン基であり、
    Yは酸素、窒素又は硫黄の原子であり、
    nは0、1、2及び3から選択され、
    mは0又は1であり、
    3は、印がついていない結合によって示されるように連結される、式A、B、C、D、E及びF:

    Figure 2012522763

    (式中、R4、R5、R6及びR7は独立して水素、C1−C6−アルキル、C1−C6−チオアルキル、C1−C6−アルコキシ、C6−C12−アリールオキシ又はC6−C12−チオアリール基、C1−C6−アルカノイル又はC7−C13−アロイル基、アミノ、C1−C6−アルキルアミノ、C1−C6−ジアルキルアミノ、C3−C12−シクロアルキルアミノ、C3-12−ヘテロシクロアルキルアミノ、C1−C6−アルキルスルホニル、C6−C12−アリールスルホニル、ハロゲン、C1−C6−ハロアルキル、例えばトリフルオロメチル、シアノ、ニトロ又はヘテロアリール基から選択され、或いは残基R4、R5、R6及びR7の2個以上が一緒になって脂肪族若しくはヘテロ脂肪族環又は芳香族若しくはヘテロ芳香族環を表す)から選択されるピリジン基であり、
    Pは中央ユニット、例えば平面ユニットであり、例えば1,3,4−オキサジアゾール−2,5−ジイル、1,2,4−オキサジアゾール−3,5−ジイル、4−メチル−4H−1,2,4−トリアゾール−3,5−ジイル、1,3,5−トリアジン−2,4−ジイル、1,2,4−トリアジン−3,5−ジイル、2H−テトラゾール−2,5−ジイル、1,2,3−チアジアゾール−4,5−ジイル、アルキルがメチル、エチル、n−プロピル及びn−ブチルで表わされ、またアルコキシがメトキシ、エトキシ、n−プロポキシ及びイソプロポキシで表わされる1−アルキル−3−(アルコキシカルボニル)−1H−ピロール−2,5−ジイル、アルキルがメチル、エチル、n−プロピル及びn−ブチルで表わされる1−アルキル−1H−ピロール−2,5−ジイル、チアゾール−2,4−ジイル、1−H−ピラゾール−1,5−ジイル、ピリミジン−2,4−ジイル、オキサゾール−2,4−ジイル、カルボニル、1H−イミダゾール−1,5−ジイル、イソキサゾール−3,5−ジイル、フラン−2,4−ジイル、アルコキシがメトキシ、エトキシ、n−プロポキシ及びイソプロポキシで表わされる3−アルコキシカルボニルフラン−2,4−ジイル、ベンゼン−1,3−ジイル並びに(Z)−1−シアノエテン−1,2−ジイルの位置異性体から選択されるものである。)
JP2012503350A 2009-04-01 2010-03-31 ニトロカテコール誘導体を含む医薬製剤及びその製造方法 Active JP5864409B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16577809P 2009-04-01 2009-04-01
US61/165,778 2009-04-01
PCT/PT2010/000014 WO2010114404A1 (en) 2009-04-01 2010-03-31 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015168152A Division JP6239561B2 (ja) 2009-04-01 2015-08-27 ニトロカテコール誘導体を含む医薬製剤及びその製造方法

Publications (3)

Publication Number Publication Date
JP2012522763A JP2012522763A (ja) 2012-09-27
JP2012522763A5 true JP2012522763A5 (ja) 2013-05-16
JP5864409B2 JP5864409B2 (ja) 2016-02-17

Family

ID=42225014

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012503350A Active JP5864409B2 (ja) 2009-04-01 2010-03-31 ニトロカテコール誘導体を含む医薬製剤及びその製造方法
JP2015168152A Active JP6239561B2 (ja) 2009-04-01 2015-08-27 ニトロカテコール誘導体を含む医薬製剤及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015168152A Active JP6239561B2 (ja) 2009-04-01 2015-08-27 ニトロカテコール誘導体を含む医薬製剤及びその製造方法

Country Status (16)

Country Link
US (4) US9132094B2 (ja)
EP (1) EP2413912B1 (ja)
JP (2) JP5864409B2 (ja)
KR (4) KR102023255B1 (ja)
CN (2) CN102448444B (ja)
AU (1) AU2010231961B2 (ja)
BR (1) BRPI1014865B1 (ja)
CA (1) CA2757411C (ja)
DK (1) DK2413912T3 (ja)
ES (1) ES2730678T3 (ja)
MX (1) MX340360B (ja)
PL (1) PL2413912T3 (ja)
PT (1) PT2413912T (ja)
RU (2) RU2011144145A (ja)
TR (1) TR201908590T4 (ja)
WO (1) WO2010114404A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
SI2481410T1 (sl) 2007-01-31 2017-01-31 Bial - Portela & Ca., S.A. Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
DK2413912T3 (da) 2009-04-01 2019-06-17 Bial Portela & Ca Sa Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
SI2694471T1 (sl) * 2011-04-08 2017-12-29 Bracco Imaging S.P.A. Postopek priprave sulfatiranega derivata 3,5-dijodo-O-(3-jodofenil)-L-tirozina
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ,エス.アー. パーキンソン病を遅延させるための医薬
US20200170291A1 (en) * 2017-05-23 2020-06-04 Particle Dynamics International, Llc Processes for producing lactitol granulates and granulates produced thereby
WO2020072886A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
WO2020072884A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
EP4117637A1 (en) 2020-03-13 2023-01-18 Bial-Portela & CA, S.A. Micronised opicapone
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
EP4262798A1 (en) 2020-12-17 2023-10-25 Bial-Portela & CA, S.A. Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) 1921-07-25 1925-04-07 Louis A Godbold Lubricator
FR1260080A (fr) 1960-03-22 1961-05-05 Materiel De Forage Soc De Fab Trépan à molettes étanche
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4085563A (en) * 1977-01-31 1978-04-25 Campbell Soup Company Cookie dispensing apparatus
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4386668A (en) 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
US4368668A (en) * 1981-05-15 1983-01-18 Veb Kombinat Polygraph "Werner Lamberz" Leipzig Printing plate mounting arrangement
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE3840954A1 (de) 1988-12-05 1990-06-07 Shell Int Research Herstellung von 2-chlornicotinsaeureestern
EP0462639A1 (en) 1990-06-05 1991-12-27 Shell Internationale Researchmaatschappij B.V. Preparation of 2-chloropyridine derivatives
EP0487774B1 (en) 1990-11-29 1994-10-26 Wei Ming Pharmaceutical Mfg. Co. Ltd. A direct tabletting auxiliary
AU3171493A (en) 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2730322B1 (fr) 1995-02-02 1997-04-30 Imago Monture de lunettes metallique
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
DE19628617A1 (de) 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
US6206110B1 (en) 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
IL138522A0 (en) 1998-03-27 2001-10-31 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
IL131037A (en) 1999-07-22 2004-06-20 Israel Atomic Energy Comm Method for making threedimensional photonic band-gap crystals
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
KR100875222B1 (ko) 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
JP3850189B2 (ja) * 1999-10-13 2006-11-29 信越化学工業株式会社 固形製剤とその製造方法
FI20000635A0 (fi) 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
JP3965361B2 (ja) 2000-08-24 2007-08-29 佐川急便株式会社 物流又は運送に関わるサービス料金のカード決済方法及びそのシステム
CN1166626C (zh) 2000-08-30 2004-09-15 李凌松 三或四取代苯基化合物、其制备方法及应用
US20030027253A1 (en) * 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제
ATE375340T1 (de) 2001-02-21 2007-10-15 Nps Pharma Inc Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten
US6761905B2 (en) * 2001-05-01 2004-07-13 Wei Ming Pharmaceutical Mfg. Co., Ltd. Process for the preparation of direct tabletting formulations and aids
AU2002310187A1 (en) 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
MXPA03011196A (es) 2001-06-08 2004-10-28 Cytovia Inc 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos.
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
HUP0402092A3 (en) 2001-07-26 2010-06-28 Merck Patent Gmbh Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions
JP4379853B2 (ja) * 2001-10-05 2009-12-09 惠民製藥股▲分▼有限公司 直接錠剤化用調合物および補助剤の調合方法
WO2004058253A1 (en) 2002-12-18 2004-07-15 Cytovia, Inc. 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
ATE455546T1 (de) 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
AU2004275470B2 (en) 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
US7300406B2 (en) 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
EP1625849A1 (en) 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
JP4717414B2 (ja) * 2004-11-08 2011-07-06 富田製薬株式会社 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
EP1827453A1 (en) 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
JP2008525524A (ja) 2004-12-28 2008-07-17 アストラゼネカ・アクチエボラーグ アリールスルホンアミドモジュレーター
US20080051441A1 (en) 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
ATE477253T1 (de) 2005-04-26 2010-08-15 Neurosearch As Neuartige oxadiazol-derivate und deren medizinische verwendung
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP2298734A3 (en) 2005-06-03 2011-07-13 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) * 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
US20090000437A1 (en) 2005-07-14 2009-01-01 Provo Craft And Novelty, Inc. Methods for Cutting
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
FR2889525A1 (fr) 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
WO2007061862A2 (en) 2005-11-18 2007-05-31 Janssen Pharmaceutica N.V. 2-keto-oxazoles as modulators of fatty acid amide hydrolase
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び/又は沈着に起因する疾患の診断薬及び治療薬
WO2007097333A1 (ja) * 2006-02-20 2007-08-30 Asahi Breweries, Ltd. 顆粒、錠剤およびそれらの製造方法
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
JP2008162955A (ja) * 2006-12-28 2008-07-17 Chugai Pharmaceut Co Ltd バリン含有高密度顆粒剤
SI2481410T1 (sl) 2007-01-31 2017-01-31 Bial - Portela & Ca., S.A. Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
TWI503128B (zh) * 2007-07-31 2015-10-11 Ajinomoto Kk A granule preparation containing an amino acid with excellent taste
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
WO2009038145A1 (ja) * 2007-09-19 2009-03-26 Asahi Breweries, Ltd. 漢方エキス、生薬エキスあるいは天然物抽出エキスまたはそれらの混合物等の天然物由来物質を含有する顆粒物の製造方法およびその顆粒物から製造する錠剤の製造方法
EP2259777A2 (en) 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
EP2307020B1 (en) 2008-07-29 2019-02-20 Bial-Portela & CA, S.A. Administration regime for nitrocatechols
US8827197B2 (en) 2008-11-04 2014-09-09 Microgreen Polymers Inc Apparatus and method for interleaving polymeric roll for gas impregnation and solid-state foam processing
DK2413912T3 (da) 2009-04-01 2019-06-17 Bial Portela & Ca Sa Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
DK2413913T3 (da) 2009-04-01 2022-06-13 Bial Portela & Ca Sa Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf
WO2011107653A2 (en) 2010-03-04 2011-09-09 Orion Corporation Method for treating parkinson's disease
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor

Similar Documents

Publication Publication Date Title
JP2012522763A5 (ja)
JP2009533423A5 (ja)
JP2010031025A5 (ja)
KR102346508B1 (ko) 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물
JP2014525420A5 (ja)
AU2015335783B2 (en) Tricyclic atropisomer compounds
EA200970656A1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
RU2008143670A (ru) Новые фармацевтические соединения
JP2008511683A5 (ja)
JP2009533410A5 (ja)
JP2016525075A5 (ja)
JP2002529532A5 (ja)
JP2013544261A5 (ja)
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
JP2009511490A5 (ja)
JP2016517417A5 (ja)
JP2018526416A5 (ja)
JP2009526830A5 (ja)
JP2018525375A5 (ja)
JP2013531029A5 (ja)
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
RU2011144145A (ru) Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
JP2018526419A5 (ja)
WO2012012478A1 (en) Aldosterone synthase inhibitors
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique